Predict your next investment

Antiva Biosciences company logo
HEALTHCARE | Biotechnology
antivabio.com

See what CB Insights has to offer

Total Raised

$56.97M

Investors Count

10

Deal Terms

3

Antiva Biosciences Funding, Antiva Biosciences Valuation & Antiva Biosciences Revenue

7 Fundings

Antiva Biosciences's latest funding round was a Series C - II for $15M on July 11, 2018.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

7/11/2018

Series C - II

$15M

$0.00B

((9.99x))

FY 1234

3

3/28/2017

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

6/11/2015

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

12/23/2014

Series A - II

$99M

$0.00B

((9.99x))

FY 1234

10

7/10/2014

Debt

$99M

$0.00B

((9.99x))

FY 1234

10

Date

7/11/2018

3/28/2017

6/11/2015

12/23/2014

7/10/2014

Round

Series C - II

Series C

Series B

Series A - II

Debt

Amount

$15M

$99M

$99M

$99M

$99M

Investors

Valuation

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

3

10

10

10

10

Antiva Biosciences Deal Terms

3 Deal Terms

Antiva Biosciences's deal structure is available for 3 funding rounds, including their Series C from March 28, 2017.

Round

Series C

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series C

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

Antiva Biosciences Investors

10 Investors

Antiva Biosciences has 10 investors. Canaan Partners invested in Antiva Biosciences's Series C - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

6/11/2015

7/11/2018

3
Series B, Series C (2017), Series C - II (2018)

Venture Capital

California

6/11/2015

7/11/2018

3
Series B, Series C (2017), Series C - II (2018)

Venture Capital

California

3/28/2017

7/11/2018

2
Series C, Series C - II (2018)

Venture Capital

Pennsylvania

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporate Venture

Maryland

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Canada

First funding

6/11/2015

6/11/2015

3/28/2017

00/00/0000

00/00/0000

Last Funding

7/11/2018

7/11/2018

7/11/2018

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Rounds

3
Series B, Series C (2017), Series C - II (2018)
3
Series B, Series C (2017), Series C - II (2018)
2
Series C, Series C - II (2018)

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Venture Capital

Venture Capital

Corporate Venture

Venture Capital

Location

California

California

Pennsylvania

Maryland

Canada

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.